Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix
- PMID: 7506116
- DOI: 10.1002/1097-0142(19940101)73:1<148::aid-cncr2820730125>3.0.co;2-c
Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix
Abstract
Background: The overexpression of c-erbB-2 protein is a prognostic marker in patients with breast cancer. Alteration of the c-erbB-2 oncogene in development of adenocarcinoma of the uterine cervix, an unfavorable gynecologic neoplasm, is unknown.
Methods: To clarify the role of the c-erbB-2 oncogene in adenocarcinoma of the uterine cervix, formalin-fixed, paraffin-embedded tissue sections from 44 cases of cervical adenocarcinoma were immunohistochemically examined for expression of c-erbB-2 protein and for c-erbB-2 gene amplification in DNA by slot blot-hybridization analysis.
Results: The expression of c-erbB-2 protein was detected in 34 cases (77%). Strong expression on cell membranes was detected in 11 cases (25%). Most cases with strong membrane expression of c-erbB-2 protein also showed amplification of the c-erbB-2 gene by slot blot-hybridization. Expression of the protein on cell membranes was more often seen at clinical Stage II or III (9 of 23 [39%]) than at Stage 0 or 1 (2 of 21 [9%]) (P < 0.05, Fisher's exact test). Expression of the c-erbB-2 protein was also associated with poorer prognosis of patients with cervical adenocarcinoma by comparison of survival curves (P < 0.005) and by the Cox regression model analysis.
Conclusions: Overexpression of c-erbB-2 protein is associated with amplification of c-erbB-2 gene and frequently occurred in cervical adenocarcinomas of the patients with poor prognoses.
Similar articles
-
Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.Cancer. 1993 Dec 1;72(11):3179-84. doi: 10.1002/1097-0142(19931201)72:11<3179::aid-cncr2820721108>3.0.co;2-#. Cancer. 1993. PMID: 7902202
-
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.Cancer. 1994 Apr 1;73(7):1785-94. doi: 10.1002/1097-0142(19940401)73:7<1785::aid-cncr2820730703>3.0.co;2-0. Cancer. 1994. PMID: 7907940
-
Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix.Cancer. 1995 May 15;75(10):2523-9. doi: 10.1002/1097-0142(19950515)75:10<2523::aid-cncr2820751019>3.0.co;2-l. Cancer. 1995. PMID: 7736397
-
Neu (c-erbB-2), a tumor marker in carcinoma of the female breast.Pathobiology. 1990;58(6):297-303. doi: 10.1159/000163601. Pathobiology. 1990. PMID: 1981830 Review.
-
Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.Semin Cancer Biol. 1993 Feb;4(1):19-26. Semin Cancer Biol. 1993. PMID: 8095411 Review.
Cited by
-
Association of replication error positive phenotype with lymphocyte infiltration in endometrial cancers.Jpn J Cancer Res. 1998 Sep;89(9):895-902. doi: 10.1111/j.1349-7006.1998.tb00646.x. Jpn J Cancer Res. 1998. PMID: 9818024 Free PMC article.
-
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.PLoS One. 2021 Sep 30;16(9):e0257976. doi: 10.1371/journal.pone.0257976. eCollection 2021. PLoS One. 2021. PMID: 34591928 Free PMC article.
-
Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.Mod Pathol. 2017 Nov;30(11):1633-1641. doi: 10.1038/modpathol.2017.80. Epub 2017 Jul 21. Mod Pathol. 2017. PMID: 28731050
-
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.Theranostics. 2017 Jan 15;7(3):717-732. doi: 10.7150/thno.17154. eCollection 2017. Theranostics. 2017. PMID: 28255362 Free PMC article.
-
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.Mol Diagn Ther. 2013 Apr;17(2):85-99. doi: 10.1007/s40291-013-0024-9. Mol Diagn Ther. 2013. PMID: 23529353 Free PMC article. Review.